Votes go against agency scientists' recommendation to keep them off the compounding list

A FDA advisory committee will review evidence surrounding peptides. Experts are concerned there is a paucity of evidence to back their approval for legal compounding.

An FDA panel is reviewing seven peptides for potential approval, sparking concerns about their widespread use in compounding pharmacies and the gray market.